4.1 OBRA '90 Mandates & Prospective Drug Utilization Review (DUR)

4.1 OBRA '90 Mandates & Prospective Drug Utilization Review (DUR)

The Omnibus Budget Reconciliation Act of 1990 (OBRA '90) represents one of the most transformative federal statutes in the history of American pharmacy practice. Enacted by the United States Congress, OBRA '90 fundamentally shifted the legal standard of care for pharmacists from a traditional focus on accurate dispensing (product-oriented practice) to comprehensive pharmaceutical care and patient safety (patient-oriented practice).

Although OBRA '90 was passed as a federal law specifically tying pharmacy practice mandates to state Medicaid program funding eligibility, individual State Boards of Pharmacy across all 50 states subsequently incorporated these exact standards into their pharmacy practice acts and administrative rules. Consequently, as tested on the Multistate Pharmacy Jurisprudence Examination (MPJE), the mandates of OBRA '90 apply to all retail and community pharmacy patients, regardless of whether their prescriptions are paid for by Medicaid, commercial insurance, or cash.

---

The Three Pillars of OBRA '90

OBRA '90 established a tripartite framework designed to ensure that medication therapy is medically necessary, appropriate, and unlikely to result in adverse medical outcomes. The three core operational pillars established under OBRA '90 are:

1. Prospective Drug Utilization Review (ProDUR): Real-time evaluation of prescription drug therapy by the dispensing pharmacist at the point of sale prior to dispensing.
2. Mandatory Patient Counseling Offer: The affirmative obligation of the pharmacy to offer face-to-face verbal counseling to patients or their caregivers regarding dispensed medications.
3. Patient Profile Maintenance & Retrospective DUR: The obligation to collect and maintain comprehensive patient drug histories and participate in retrospective claims data analysis overseen by state DUR boards.

---

Mechanics of Prospective Drug Utilization Review (ProDUR)

Prospective Drug Utilization Review (ProDUR) is an interactive, point-of-sale screening process performed by the licensed pharmacist prior to dispensing a new or refill prescription. The primary objective of ProDUR is to identify, evaluate, and resolve potential drug therapy problems before the patient physically receives the medication.

Modern pharmacy dispensing software automatically checks electronic prescription data against the patient's centralized profile and generates clinical warnings. However, the legal responsibility for performing ProDUR rests entirely on the licensed pharmacist, not the software vendor or computer system.

The 7 Mandatory DUR Screening Categories

Under federal OBRA '90 regulations (42 CFR § 456.705) and corresponding state pharmacy regulations, the pharmacist must screen every prescription presented for dispensing against seven mandatory clinical categories:

1. Therapeutic Duplication

Therapeutic duplication occurs when a patient is prescribed two or more medications containing the same active ingredient or belonging to the same pharmacological/therapeutic class without clinical justification.

• Clinical Example: A patient presenting a new prescription for lisinopril while currently taking enalapril, or concurrently taking two systemic Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) such as ibuprofen and naproxen, which increases gastrointestinal toxicity without additive efficacy.

2. Drug-Disease Contraindications

Drug-disease contraindications occur when a prescribed drug has the potential to exacerbate an existing medical condition or chronic disease state.

• Clinical Example: Prescribing a non-selective beta-blocker (e.g., propranolol) to a patient with documented severe asthma or Chronic Obstructive Pulmonary Disease (COPD), triggering bronchospasm, or dispensing systemic oral decongestants (e.g., pseudoephedrine) to a patient with uncontrolled severe hypertension.

3. Drug-Drug Interactions

Drug-drug interactions occur when co-administered medications alter the efficacy, absorption, metabolism, or toxicity profile of one or both drugs. The screening must also evaluate potential interactions between prescription drugs and non-prescription (OTC) medications or dietary supplements listed in the patient profile.

• Clinical Example: Dispensing fluconazole or amiodarone to a patient stabilized on warfarin, leading to severe cytochrome P450 inhibition, elevated International Normalized Ratio (INR), and life-threatening hemorrhage risk.

4. Incorrect Drug Dosage or Duration of Treatment

Pharmacists must evaluate whether the prescribed dose, frequency, route, and total duration of therapy fall within established FDA-approved or evidence-based clinical guidelines, taking into account patient-specific factors such as renal function, hepatic function, age, and weight.

• Clinical Example: Dispensing oral ketorolac for a 14-day supply (federal guidelines explicitly limit ketorolac therapy to a maximum of 5 consecutive days due to severe renal impairment and GI ulceration risks), or failing to adjust renal dosing for gabapentin or levofloxacin in an elderly patient with reduced CrCl.

5. Drug-Allergy Interactions and Cross-Reactivity

Pharmacists must verify that the prescribed drug does not conflict with documented drug allergies or known hypersensitivity reactions recorded in the patient profile, including evaluating potential immunological cross-reactivity.

• Clinical Example: Dispensing amoxicillin to a patient with a documented history of penicillin-induced anaphylaxis, or dispensing a sulfonamide antibiotic (e.g., sulfamethoxazole/trimethoprim) to a patient with a known severe sulfa allergy.

6. Clinical Abuse or Misuse

The pharmacist must screen for patterns indicative of irrational drug use, psychological dependency, addiction, diversion, or patient misdirection. This includes monitoring refill frequencies, overlapping prescriptions from multiple prescribers ("doctor shopping"), and early refill requests for controlled substances.

• Clinical Example: A patient requesting a 30-day refill for oxycodone/acetaminophen 12 days after the previous fill was dispensed, or obtaining concurrent benzodiazepine and opioid prescriptions from three different prescribers.

7. Drug-Prescriber / Over- and Under-Utilization

Pharmacists must assess whether the patient is overutilizing (taking higher doses or refilling too frequently) or underutilizing (non-adherence, delayed refills) their prescribed regimen. Under-utilization of maintenance therapies for chronic conditions (e.g., statins, antihypertensives, inhalers) represents a major cause of preventable hospitalizations.

---

Pharmacist Legal Duty & Overriding Alert Fatigue

In modern practice, pharmacy computer systems frequently generate automated alert pop-ups for minor or theoretical drug interactions. This phenomenon, known as alert fatigue, creates a significant risk that pharmacists might bypass pop-ups without conducting a meaningful clinical review.

On the MPJE, it is a critical legal rule that computerized DUR alerts do not satisfy or shift the pharmacist's legal liability. If a computer system flags a high-risk DUR warning (such as a severe drug interaction or contraindication) and the pharmacist overrides the alert without conducting a proper evaluation, contacting the prescriber, or documenting a clinical rationale, the pharmacist is held legally liable for any resulting patient injury under both tort law and administrative pharmacy board discipline.

When a prospective DUR screening flags a potential problem, the pharmacist must exercise professional judgment to determine the appropriate intervention:

1. Gather Patient Context: Review patient profile notes, previous refill history, or consult the patient directly.
2. Contact the Prescriber: If a clinically significant contraindication, incorrect dose, or major interaction exists, the pharmacist must contact the prescriber to discuss alternative therapy or monitoring.
3. Refuse to Dispense: If the prescriber insists on an unsafe regimen that threatens patient safety, the pharmacist has the legal authority and duty to refuse to dispense the prescription.
4. Document Resolution: All DUR interventions, prescriber consultations, and clinical justifications must be contemporaneously documented in the pharmacy record system.

---

Prospective DUR vs. Retrospective DUR Comparison

---

Summary Table: 7 Mandatory DUR Screening Categories